1589314014021_5ebaf5bc8fd6a60004fbd876_logo.png
Navidea Biopharmaceuticals Announces Full Enrollment in its Ongoing Phase 2B Trial of Tc99m Tilmanocept in Rheumatoid Arthritis (RA)
June 15, 2020 08:00 ET | Navidea Biopharmaceuticals, Inc.
DUBLIN, OH, June 15, 2020 (GLOBE NEWSWIRE) -- Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic...
Therapeutics Solutions International, Inc LOGO.png
Therapeutic Solutions International Inc. Reports Revenues Up 850% for Q2
August 29, 2019 13:53 ET | Therapeutic Solutions International, Inc.
OCEANSIDE, Calif., Aug. 29, 2019 (GLOBE NEWSWIRE) -- via NetworkWire - Therapeutics Solutions International Inc. (OTC: TSOI) today reports that its second-quarter 2019 revenues increased 850%, as...
Therapeutics Solutions International, Inc LOGO.png
Therapeutic Solutions International Announces Positive Clinical Data Using NanoStilbene™ to Stimulate Immune System in Advanced Cancer Patients
August 26, 2019 09:00 ET | Therapeutic Solutions International, Inc.
OCEANSIDE, Calif., Aug. 26, 2019 (GLOBE NEWSWIRE) -- via NetworkWire -- Therapeutics Solutions International, Inc., (OTC Markets: TSOI) announced today positive results from a pilot clinical trial...
Therapeutics Solutions International, Inc LOGO.png
Therapeutic Solutions International Collaborates with Right to Try Foundation on Novel Means of Protecting Patients While Hyper-accelerating Drug Development
August 05, 2019 09:00 ET | Therapeutic Solutions International, Inc.
OCEANSIDE, Calif., Aug. 05, 2019 (GLOBE NEWSWIRE) -- via NetworkWire – Therapeutics Solutions International, Inc., (OTC Markets: TSOI) together with The Right to Try Foundation announced filing of a...
Therapeutics Solutions International, Inc LOGO.png
NanoStilbene™ Nutraceutical Shown to Increase Ability of Cyclophosphamide Chemotherapy to Suppress Cancer
July 29, 2019 09:00 ET | Therapeutic Solutions International, Inc.
OCEANSIDE, Calif., July 29, 2019 (GLOBE NEWSWIRE) -- NetworkWire – Therapeutics Solutions International, Inc., (OTC Markets: TSOI) reported today positive animal data demonstrating synergy at...
VBI-Vaccines-Vertical-Logo.png
VBI Vaccines Announces Dosing of First Recurrent GBM Patient in Part B of Ongoing Phase 1/2a Study of VBI-1901
July 29, 2019 08:00 ET | VBI Vaccines, Inc.
— Part B of the study, a subsequent extension of the optimal dose from Part A, to enroll 10 first-recurrent GBM patients— Initial immunologic data from Part B expected around year-end 2019— Expanded...
Therapeutics Solutions International, Inc LOGO.png
Therapeutic Solutions International Reports its NanoStilbene™ Nutraceutical Product Enhances Efficacy of FDA Cleared Cancer Immunotherapy in Animal Model of Cancer
July 22, 2019 09:00 ET | Therapeutic Solutions International, Inc.
OCEANSIDE, Calif., July 22, 2019 (GLOBE NEWSWIRE) -- via NetworkWire -- Therapeutics Solutions International, Inc. (OTC Markets: TSOI) reported today positive animal data demonstrating synergy...
VBI-Vaccines-Vertical-Logo.png
VBI Vaccines Reports Data from Part A of the Ongoing Phase 1/2a Study of VBI-1901 in Recurrent Glioblastoma (GBM) Patients at ASCO 2019
June 04, 2019 08:00 ET | VBI Vaccines, Inc.
  Well tolerated at all doses with no safety signalsThree patients in high dose (10 µg) cohort showed evidence of stable disease by MRI10 µg dose selected for Part B of the study, which is expected...
National Brain Tumor Society Cites Ten Reasons for Brain Tumor Community Excitement in 2017
January 10, 2017 17:35 ET | National Brain Tumor Society
BOSTON, MA--(Marketwired - January 10, 2017) - National Brain Tumor Society (NBTS), the largest nonprofit dedicated to the brain tumor community, enters 2017 with greater enthusiasm about its mission...
Stellar Biotechnologies to Present at ImVacS 2012 Summit on August 13-16, 2012
June 25, 2012 10:55 ET | Stellar Biotechnologies, Inc.
PORT HUENEME, CA--(Marketwire - Jun 25, 2012) -  Stellar Biotechnologies, Inc. ("Stellar") (TSX VENTURE: KLH) (PINKSHEETS: SBOTF) (FRANKFURT: RBT) is pleased to report that an abstract prepared...